You're contacting media contact of this press release

Title: Med Consumer Watch Study Identifies CoreAge Rx as High-Value Provider in GLP-1 Telehealth Sector

Savannah, GA, United States, 29th Jan 2026 - Med Consumer Watch, an independent healthcare consumer research organization, has published the results of a comprehensive study comparing 65 telehealth providers offering GLP-1 medications. The analysis found that CoreAge Rx, a telehealth clinic specializing in GLP-1 medication access for weight management and metabolic care, delivers a notable combination of pricing transparency, clinical oversight, and affordability relative to peer providers.The study, conducted in late 2025, evaluated online care providers on multiple criteria, including pricing structures, fee transparency, clinician qualifications, and telehealth care delivery practices. CoreAge Rx distinguished itself by offering clear, flat-rate monthly pricing without additional membership fees or hidden costs. According to the report, CoreAge Rx’s pricing begins at $99 per month for semaglutide and $149 per month for tirzepatide, with all care provided under the supervision of board-certified physicians.Med Consumer Watch’s analysis reflects increasing consumer demand for transparent and accessible care options within the expanding GLP-1 treatment market. GLP-1 medications, such as semaglutide and tirzepatide, are approved by regulatory authorities for metabolic and weight-related care and have seen rapid adoption across telehealth platforms. The report highlights variability in pricing models and clinical practices among the 65 providers analyzed, with CoreAge Rx scoring above average in key categories associated with consumer value.In an objective summary of findings, the Med Consumer Watch report noted that CoreAge Rx’s pricing structure and clinical oversight suggest that patients can access medically supervised GLP-1 care without sacrificing affordability. The...

This press release is issued by King Newswire